1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for people in Idalia who are battling with opioid abuse and addiction is called opioid maintenance therapy. Some clinics and doctors are authorized to dispense specific medications to opioid addicted individuals, many that are opioid-based themselves and are addictive. With low enough doses however, the individual doesn't feel high but also does not have acute cravings and isn't experiencing opioid withdrawal. Methadone is the first medication used for this reason, but there are a few more options currently to pick from.
Methadone is an opioid and is meant to be taken at an out-patient medical center certified to administer the med, which is taken daily as a pill or liquid. The price of the med is approximately under $200 per month. Buprenorphine is also an opioid based drug, and is a pill often taken every other day. But different from Methadone that is only be administered in well-regulated clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately just under $300 monthly for the generic version of the drug. There is also a type of buprenorphine containing the drug naloxone, which is a drug that reverses the effects of opioids. An individual taking this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced approximately $450 a month. Naltrexone is another drug taken in opioid maintenance therapy, but unlike the other medications mentioned it's an opiate blocker and is not an opioid. There is an option to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, the drug prevents a person from getting high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 /month.
For All Drug and Alcohol Rehabilitation Facilities In Idalia, Click Here.
